CogState Ltd
ABN 80 090 975 723

Level 7
21 Victoria Street
Melbourne Vic 3000
Australia

ASX Announcement

COGSTATE PLACEMENT TO INCREASE SALES RESOURCES

Melbourne, Thursday 15th December 2005

Share Placement

CogState Limited (ASX:**CGS**) is pleased to announce that the company has placed 3 million fully paid ordinary shares at an issue price of A$0.10 per share.

The placement has been arranged by Taylor Collison Limited ("**Taylor Collison**") to sophisticated investors.

All shares issued in the placement will rank equally with existing ordinary shares on issue.

The placement represents 8.43% of the current shares on issue. Following the placement, the Company will have 38,597,749 shares on issue.

The funds raised by the placement will be directed to working capital, specifically additional sales resources in North America and Europe, where the company is aggressively growing sales of its diagnostic tests into its key market; clinical trials of pharmaceutical and biotechnology companies.

Brad O'Connor - Chief Executive Officer

For further information, please contact:

Mr Brad O'Connor
Chief Executive Officer
CogState Limited
Ph: 0411 888 347

Mr Craig Ball
Director
Taylor Collison Ltd
Ph: 08 8217 3900

About CogState

CogState Ltd specializes in the development and commercialization of Clinical Information Technology (ClinIT) software. Current products measure brain function and have application for use in clinical trials conducted by Pharmaceutical and Biotechnology companies to show the effects of drugs on the brain. Additional products are sports concussion return-to-play tests purchased by sporting organizations, fitness to operate tests purchased by corporations in the work safety market, and direct-to-consumer tests purchased by individuals wishing to evaluate their cognitive function (to detect early Alzheimer's Disease, or the effect of drugs or diseases on brain function).